The Market LogEnter at least 2 characters. Company and ticker searches are not case-sensitive.

Transaction #23617 · Form 4 · 0001539215-25-000008

SUPERNUS PHARMACEUTICALS, INC. · Exercise / conversion · Common Stock

SUPERNUS PHARMACEUTICALS, INC. · Transacted December 18, 2025 · Filed December 19, 2025

Original SEC filing ↗

What does this filing report?

An SEC Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. records an exercise / conversion involving Common Stock on December 18, 2025. The reported quantity was 1,500. The filing date is December 19, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Transaction details

Company CIK
0001356576
Security type
Non-derivative
Acquisition type
Exercise / conversion · Code M
Quantity acquired
1,500
Reported price
0
Reference value
0
Currency
Currency not specified
Ownership
Direct
Holdings after transaction
15,218
Ownership description
Not reported
SEC acceptance time
Dec 19, 2025, 4:05 PM EST
10b5-1 indication
Not indicated

Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.

Reporting owners

These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.

Company listings

SUPN · Nasdaq · linked security

The linked listing is identified separately from other current company listings.

Filing footnotes & remarks

F1
Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F2
On February 22, 2022, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2022.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.

This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.